Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies

Silvia Mosulén, Leticia Ortí, Esperanza Bas Infante, Rodrigo J. Carbajo, Antonio Pineda-Lucena

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Heparanase is an endo-β-D-glucosidase capable of specifically degrading heparan sulphate, one of the main components of the extracellular matrix. This 65 kDa polypeptide is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in antitumour treatments. Structure-based approaches to find inhibitors of heparanase have been historically hampered by the lack of success in crystallizing the protein. With the aim to undertake the NMR structural characterisation of heparanase, we have designed and produced, using recombinant methods, smaller constructs of heparanase containing the catalytically active glutamic acids and the two binding sites for heparan sulphate. An extensive range of expression and purification conditions were evaluated to alleviate the intrinsic low solubility and aggregation propensity of heparanase, allowing the obtention of the enzyme in milligram quantities, both unlabelled and 15N-labelled for NMR studies. Using the smallest of the designed constructs and applying NMR and SPR methodologies, we have demonstrated that known inhibitors of heparanase bind to this construct specifically and selectively with K D values in the range of those reported for human heparanase, validating it for future drug discovery projects focused on the identification of novel inhibitors of this enzyme.

Original languageEnglish (US)
Pages (from-to)151-160
Number of pages10
JournalBiopolymers
Volume95
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Drug Discovery
Magnetic Resonance Spectroscopy
Nuclear magnetic resonance
Enzymes
Polypeptides
Binding sites
Heparitin Sulfate
Purification
Tumors
Agglomeration
Solubility
Proteins
Glutamates
Glucosidases
Acids
Enzyme Inhibitors
heparanase
Extracellular Matrix
Neoplasms
Binding Sites

Keywords

  • drug discovery
  • expression
  • heparan sulphate
  • heparanase
  • NMR
  • purification
  • SPR

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Biomaterials
  • Organic Chemistry

Cite this

Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies. / Mosulén, Silvia; Ortí, Leticia; Bas Infante, Esperanza; Carbajo, Rodrigo J.; Pineda-Lucena, Antonio.

In: Biopolymers, Vol. 95, No. 2, 02.2011, p. 151-160.

Research output: Contribution to journalArticle

Mosulén, Silvia ; Ortí, Leticia ; Bas Infante, Esperanza ; Carbajo, Rodrigo J. ; Pineda-Lucena, Antonio. / Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies. In: Biopolymers. 2011 ; Vol. 95, No. 2. pp. 151-160.
@article{dccf7c6a298349a4bf98954920607dbd,
title = "Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies",
abstract = "Heparanase is an endo-β-D-glucosidase capable of specifically degrading heparan sulphate, one of the main components of the extracellular matrix. This 65 kDa polypeptide is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in antitumour treatments. Structure-based approaches to find inhibitors of heparanase have been historically hampered by the lack of success in crystallizing the protein. With the aim to undertake the NMR structural characterisation of heparanase, we have designed and produced, using recombinant methods, smaller constructs of heparanase containing the catalytically active glutamic acids and the two binding sites for heparan sulphate. An extensive range of expression and purification conditions were evaluated to alleviate the intrinsic low solubility and aggregation propensity of heparanase, allowing the obtention of the enzyme in milligram quantities, both unlabelled and 15N-labelled for NMR studies. Using the smallest of the designed constructs and applying NMR and SPR methodologies, we have demonstrated that known inhibitors of heparanase bind to this construct specifically and selectively with K D values in the range of those reported for human heparanase, validating it for future drug discovery projects focused on the identification of novel inhibitors of this enzyme.",
keywords = "drug discovery, expression, heparan sulphate, heparanase, NMR, purification, SPR",
author = "Silvia Mosul{\'e}n and Leticia Ort{\'i} and {Bas Infante}, Esperanza and Carbajo, {Rodrigo J.} and Antonio Pineda-Lucena",
year = "2011",
month = "2",
doi = "10.1002/bip.21549",
language = "English (US)",
volume = "95",
pages = "151--160",
journal = "Biopolymers - Peptide Science Section",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies

AU - Mosulén, Silvia

AU - Ortí, Leticia

AU - Bas Infante, Esperanza

AU - Carbajo, Rodrigo J.

AU - Pineda-Lucena, Antonio

PY - 2011/2

Y1 - 2011/2

N2 - Heparanase is an endo-β-D-glucosidase capable of specifically degrading heparan sulphate, one of the main components of the extracellular matrix. This 65 kDa polypeptide is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in antitumour treatments. Structure-based approaches to find inhibitors of heparanase have been historically hampered by the lack of success in crystallizing the protein. With the aim to undertake the NMR structural characterisation of heparanase, we have designed and produced, using recombinant methods, smaller constructs of heparanase containing the catalytically active glutamic acids and the two binding sites for heparan sulphate. An extensive range of expression and purification conditions were evaluated to alleviate the intrinsic low solubility and aggregation propensity of heparanase, allowing the obtention of the enzyme in milligram quantities, both unlabelled and 15N-labelled for NMR studies. Using the smallest of the designed constructs and applying NMR and SPR methodologies, we have demonstrated that known inhibitors of heparanase bind to this construct specifically and selectively with K D values in the range of those reported for human heparanase, validating it for future drug discovery projects focused on the identification of novel inhibitors of this enzyme.

AB - Heparanase is an endo-β-D-glucosidase capable of specifically degrading heparan sulphate, one of the main components of the extracellular matrix. This 65 kDa polypeptide is implicated in cancer processes such as tumour formation, angiogenesis and metastasis, making it a very attractive target in antitumour treatments. Structure-based approaches to find inhibitors of heparanase have been historically hampered by the lack of success in crystallizing the protein. With the aim to undertake the NMR structural characterisation of heparanase, we have designed and produced, using recombinant methods, smaller constructs of heparanase containing the catalytically active glutamic acids and the two binding sites for heparan sulphate. An extensive range of expression and purification conditions were evaluated to alleviate the intrinsic low solubility and aggregation propensity of heparanase, allowing the obtention of the enzyme in milligram quantities, both unlabelled and 15N-labelled for NMR studies. Using the smallest of the designed constructs and applying NMR and SPR methodologies, we have demonstrated that known inhibitors of heparanase bind to this construct specifically and selectively with K D values in the range of those reported for human heparanase, validating it for future drug discovery projects focused on the identification of novel inhibitors of this enzyme.

KW - drug discovery

KW - expression

KW - heparan sulphate

KW - heparanase

KW - NMR

KW - purification

KW - SPR

UR - http://www.scopus.com/inward/record.url?scp=78649639040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649639040&partnerID=8YFLogxK

U2 - 10.1002/bip.21549

DO - 10.1002/bip.21549

M3 - Article

VL - 95

SP - 151

EP - 160

JO - Biopolymers - Peptide Science Section

JF - Biopolymers - Peptide Science Section

SN - 0006-3525

IS - 2

ER -